

U-CyTech B.V.

Yalelaan 48 3584 CM Utrecht The Netherlands +31 85 073 1460 info@ucytech.com www.ucytech.com Data sheet **ICE Peptide Pool**

> Peptide pool of 32 HLA class I-restricted T cell epitopes of human Influenza A virus, Cytomegalovirus and Epstein-Barr virus.

Cat. No. **CT387**

Specificity To be used as an antigen-specific positive control in the human IFN-γ ELISPOT

assay. The pool consist of 32 peptides of human Influenza A virus (Flu), Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) epitopes which are recognized by CD8+ T cells and presented by 13 class I HLA-A and HLA-B alleles prevalent

among Caucasian individuals.

(Reference: Currier, J.R. et al. 2002. J. Immunol. Methods 260: 157-172)

The peptide pool can also be used as positive control in the human IL-2 and G-CSF

ELISPOT assay.

Application Reconstitute the lyophilized contents by injecting 250 µl of sterile distilled water

into the vial. Mix the solution gently for approximately 15 seconds and allow it to

stand for 2 minutes at room temperature. Avoid vigorous shaking.

Working concentration: 40x in culture medium containing human PBMC. Recommended peptide concentration: 0.5 µg peptide/ml culture medium.

Recommended cell concentration: 2x10⁵ human PBMC/well. Recommended culture volume in ELISPOT plate: 100 μl/well.

Contents Lyophilized ICE peptide pool. 32 x 5 µg peptide/vial.

Buffer prior to lyophilization: 0.25 ml PBS + 125 mM trehalose.

Preservative free.

Contained VSDGGPNLY (Influenza A, HLA-A1), CTELKLSDY (Influenza A, HLA-A1), peptides

GILGFVFTL (Influenza A, HLA-A2), FMYSDFHFI (Influenza A, HLA-A2),

CLGGLLTMV (EBV, HLA-A2), GLCTLVAML (EBV, HLA-A2),

NLVPMVATV(CMV, HLA-A2), KTGGPIYKR (Influenza A, HLA-A68), RVLSFIKGTK (Influenza A, HLA-A3), ILRGSVAHK (Influenza A, HLA-A3),

RVRAYTYSK (EBV, HLA-A3), RLRAEAQVK (EBV, HLA-A3)

SIIPSGPLK (Influenza A, HLA-A3/A11/A6), AVFDRKSDAK (EBV, HLA-A11),

IVTDFSVIK (EBV, HLA-A11), ATIGTAMYK (EBV, HLA-A11),

DYCNVLNKEF (EBV, HLA-A24), LPFDKTTVM (Influenza A, HLA-B7),

RPPIFIRRL (EBV, HLA-B7), ELRSRYWAI (Influenza A, HLA-B8), RAKFKQLL (EBV, HLA-B8), FLRGRAYGL (EBV, HLA-B8),

QAKWRLQTL (EBV, HLA-B8), SDEEEAIVAYTL (CMV, HLA-B18),

SRYWAIRTR (Influenza A, HLA-B27), ASCMGLIY (Influenza A, HLA-B27),

RRIYDLIEL (EBV, HLA-B27), YPLHEQHGM (EBV, HLA-B35), IPSINVHHY (CMV, HLA-B35), EENLLDFVRF (EBV, HLA-B44), EFFWDANDIY (CMV, HLA-B44), TPRVTGGGAM (CMV, HLA-B7).

Sterility Membrane filtered (0.2 µm)

Packaging 5 ml brown glass bottle

Storage The lyophilized peptide pool can be safely stored at 4 °C for a defined length of

time (expiry date indicated on vial).

After reconstitution, it is strongly recommended to divide the reconstituted peptides into small aliquots for single use. These aliquots should be stored at ≤ -20 °C. Under these conditions the peptides are stable for minimal two years.

General Clear powder (barely visible).

After reconstitution: a clear solution. Do not use if the solution is or has become

turbid.

Safety The product is not classified as hazardous according to Regulation (EC) no.

1272/2008.

Consult the safety data sheet (SDS) for further information regarding hazards and safe handling practices. The SDS can be found on our website www.ucytech.com.

For research use only

Version 230612